Skip to main content

Table 1 Demographic and clinical characteristics of study participants (mean & 95% CI)

From: Calcification of coronary arteries and abdominal aorta in relation to traditional and novel risk factors of atherosclerosis in hemodialysis patients

 

Hemodialysis group

Control group

Statistical significance

 

(N = 104)

(N = 14)

 

Age (years)

53.6 (50.3-56.9)

54.6 (45.1-64.1)

0.93

Gender (male/female)

56/48

6/8

0.63

Body mass index (kg/m 2 )

24.9 (23.3-26.6)

24.7 (23.9-25.6)

0.82

Obesity (BMI ≥ 30 kg/m2) (n/%)

11 / 10.6

0

0.43

Smokers (n/%)

62 / 59.6

1 / 7.1

<0.001

 Smoking burden (pack-years)

15 (12–18)

  

Family burden (n/%)

32 / 30.8

NA.

 

Primary cause of CKD (n/%)

   

Diabetes

11 / 10.6

  

Hypertension

4 / 3.8

  

Nephrolithiasis

3 / 2.9

  

Autosomal Dominant Polycystic Kidney Disease (ADPKD)

6 / 5.8

  

Ischemic nephropathy

5 / 4.8

  

Glomerulonephritis

50 / 48.1

  

Urinary tract infection

6 / 5.8

  

Amyloidosis

3 / 2.9

  

Other or unknown

16 / 15.4

  

Time on dialysis (months)

45 (33–54)

  

Kt/V (per HD session)

1.29 (1.25-1.34)

  

Co-morbidity (%)

   

Hypertension

87 / 84.5

0

 

Diabetes

19 / 18.3

0

 

Coronary artery disease

35 / 33.7

0

 

Stroke

9 / 8.7

0

 

Past kidney transplantation

18 / 17.3

-

 

Pharmacotherapy (n/%)

   

Antihypertensive

79 / 76.0

  

No of antihypertensive drugs (n)

2.0 (1.7-2.2)

  

Oral anti-diabetic*

5 / 26.3

  

Insulin*

14 / 73.7

  

Antiplatelet

52 / 50.0

  

Oral anticoagulant

9 / 8.7

  

Statins

18 / 17.3

  

Fibrates

0

  

Oral phosphorous binders

102 / 98.1

  

Carbonate calcium dose (g/day)

3.3 (2.9-3.7)

  

Sevelamer hydrochloride (g/day)

0

  

Alfacalcidol

82 / 78.8

  

Alfacalcidol dose (μg/week)

2.5 (1.1-3.8)

  
  1. * for patients with diabetes.
  2. NA. – not available.